Efficacy of once-daily Avelox for complicated abdominal infections highlighted at ICAAC
... Approximately 3.5 million Americans are diagnosed annually with cIAIs, which are caused by disease, trauma or surgery in the abdomen that can allow bacteria to lea...AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
Schering-Plough Corporation (NYSE: SGP) today reported that monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) was as effective and well tolerated as a standard multi-dose combination antibiotic regimen in the treatment of patients with complicated intra-abdominal infections (cIAI), according to results of a study involving 681 patients published in the current i...Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
KENILWORTH, N.J. AVELOX (moxifloxacin HCl) monotherapy at 400 ...mg once daily is as effective as the high-dose combination of levofloxacin (500 ...mg twice daily) plus ceftriaxone (2 g once daily) in treating patients with ...severe community-acquired pneumonia (CAP) requiring hospitalization, according ...to results of a new clinical study presented at the 16th European Congress of ...Clinical...FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) for a new use the treatment of complicated intra-abdominal infections (cIAI) in adults. AVELOX is the only marketed fluoroquinolone antibiotic approved by the FDA as monotherapy to treat this indication. The FD...